TMCnet News
Global Acute Ischemic Stroke Therapeutics Report 2016: Pipeline Review of 17 Companies & 27 drug Molecules - Research and MarketsResearch and Markets has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2016" report to their offering. Acute Ischemic Stroke pipeline therapeutics constitutes close to 27 molecules. Out of which approximately 27 molecules are developed by Companies. Our latest report Acute Ischemic Stroke - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Acute Ischemic Stroke Acute ischemic stroke is caused by a blockage in a blood vessel that stops the blood flow. The surrounding brain tissue becomes deprived of oxygen. Symptoms of acute ischemic stroke include loss of sensation and weakness in an arm, leg or one side of the body, partial loss of vision or hearing, slurred speech, double vision and dizziness. The predisposing factors include age, race, high blood pressure, diabetes mellitus, tobacco smoking, obesity, obstructive sleep apnea and dyslipidemia. The molecules developed by Companis in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 9, 5, 1 and 9 respectively. Furthermore, this report also reviews of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/xf8qfm/acute_ischemic
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005361/en/ |
